What is Roth Capital’s Forecast for Cingulate Q1 Earnings?

Cingulate Inc. (NASDAQ:CING) – Research analysts at Roth Capital boosted their Q1 2025 earnings per share (EPS) estimates for shares of Cingulate in a research report issued on Monday, March 31st. Roth Capital analyst B. Pachaiyappan now forecasts that the company will earn ($0.96) per share for the quarter, up from their prior forecast of ($2.19). Roth Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Cingulate’s current full-year earnings is ($11.69) per share. Roth Capital also issued estimates for Cingulate’s Q2 2025 earnings at ($0.72) EPS, Q3 2025 earnings at ($0.63) EPS, Q4 2025 earnings at ($0.37) EPS, FY2025 earnings at ($2.68) EPS and FY2026 earnings at ($2.48) EPS.

Other research analysts also recently issued research reports about the stock. Roth Mkm assumed coverage on shares of Cingulate in a research note on Friday, January 10th. They set a “buy” rating and a $12.00 price objective for the company. HC Wainwright restated a “buy” rating and issued a $20.00 target price on shares of Cingulate in a report on Thursday, March 6th.

Cingulate Trading Down 2.1 %

Cingulate stock opened at $4.16 on Wednesday. The stock has a fifty day moving average price of $4.24 and a 200 day moving average price of $4.43. Cingulate has a 52 week low of $1.80 and a 52 week high of $20.83. The firm has a market capitalization of $13.36 million, a P/E ratio of -0.28 and a beta of -0.83.

Institutional Investors Weigh In On Cingulate

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Commonwealth Equity Services LLC lifted its stake in shares of Cingulate by 281.5% in the 4th quarter. Commonwealth Equity Services LLC now owns 43,022 shares of the company’s stock valued at $212,000 after purchasing an additional 31,746 shares in the last quarter. Geode Capital Management LLC purchased a new position in Cingulate in the fourth quarter valued at approximately $135,000. Jane Street Group LLC purchased a new position in Cingulate in the third quarter valued at approximately $106,000. Finally, AlphaMark Advisors LLC lifted its position in Cingulate by 50,000.0% during the fourth quarter. AlphaMark Advisors LLC now owns 5,010 shares of the company’s stock valued at $25,000 after buying an additional 5,000 shares in the last quarter. 41.31% of the stock is currently owned by institutional investors and hedge funds.

About Cingulate

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.